Shared on 11 Nov 25
Fair value Increased 1.98%FRE: Future Earnings Outlook Will Reflect Balanced Profit And Risk Expectations
The analyst fair value price target for Fresenius SE KGaA has been raised from €52.36 to €53.40. This change reflects broadly improved expectations from analysts based on strengthening revenue growth and profit margin forecasts.
Shared on 28 Oct 25
Fair value Increased 4.04%The analyst consensus price target for Fresenius SE KGaA has been increased from €50.33 to €52.36. This change reflects analysts' expectations of modest revenue growth and improved fair value assessments.
Shared on 14 Oct 25
Fair value Increased 1.44%Narrative Update on Fresenius SE KGaA Analysts have raised their price target for Fresenius SE KGaA, increasing it from €49.61 to €50.33. They cite improved revenue growth and profit margin outlooks as the basis for the adjustment.
Shared on 03 Sep 25
Fair value Increased 1.17%Both the Future P/E and Net Profit Margin for Fresenius SE KGaA remained essentially stable, underpinning the marginal increase in the consensus analyst price target from €49.04 to €49.61. What's in the News Fresenius is leading the EASYGEN consortium, a public-private EU-funded initiative aiming to accelerate and cost-optimize CAR-T cell therapy manufacturing, making it more accessible across Europe using modular, hospital-based platforms.
Shared on 23 Apr 25
Fair value Decreased 0.085%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 3.34%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 17%AnalystConsensusTarget has decreased future PE multiple from 17.7x to 14.6x.
Shared on 26 Mar 25
Fair value Increased 27%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 7.97%AnalystConsensusTarget has increased future PE multiple from 14.9x to 17.2x.
Shared on 12 Mar 25
Fair value Increased 85%AnalystConsensusTarget has increased revenue growth from 2.6% to 4.5%, increased future PE multiple from 12.5x to 14.9x and decreased shares outstanding growth rate from 0.1% to 0.0%.